Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question - ResearchAndMarkets.com

DUBLIN--()--The "Interleukin-2, a Tale of Two Halves: To Suppress or Augment Suppression, That is the Question" report has been added to ResearchAndMarkets.com's offering.

This report will assess the latest developments in the interleukin-2 (IL-2) research and development and explore the novel strategies companies are adopting to augment immune response and avoid off-target effects in a wide range of conditions including metastatic melanoma, renal cell carcinoma, urothelial cancers, relapse remitting multiple sclerosis, type 1 diabetes, as well as prophylaxis post-transplant and allergic conditions.

The report provides an introduction to IL-2, when the target was identified and early commercial applications. It reviews the numerous developmental programs including Nektar Therapeutics regulated IL-2, bempegaldesleukin (previously known as NKTR-214) in phase 3, ADC Therapeutics Sarl antibody-drug conjugate ADCT-301 in phase 2, Roche's fusion protein RO6874281 in phase 2 and Medicenna's superkine MDNA109 and MDNA209 in preclinical research.

The report provides a detailed description of autoimmune responses and possible ways that drug development can augment immune responses so as to improve antitumor activity and reduce the off-target effect. It discusses the safety and off-target effects associated with approved drugs and the strategies companies have adopted to circumvent these side effect. Finally, the report provides insights into the latest trends and technologies in the IL-2 research and development, including a review of recent collaborations and identifies products and companies to watch.

The Report Includes:

  • An introduction to interleukin-2 (IL-2) and identification of its applications
  • Insights into the latest trends and technologies in the IL-2 research and development
  • Discussion of strategies adopted by IL-2 developers for the successful treatment of cancer and information on NKTR-214, a Nektar Therapeutics product
  • Review of recent VC investment in this zone highlighted by Syncona and Novartis Venture Fund recent CHF35m investment in Anaveon AG, a new Swiss Biotech company spun out from the University of Zurich which is developing a novel oncologic monoclonal antibody that boosts IL-2 but has an improved side-effect profile
  • Detailed description of autoimmune responses and possible ways to augment immune responses so as to improve antitumor activity and reduce off-target effect
  • An understanding of various conditions which may develop as an off-target effect in the cancer treatment such as metastatic melanoma (MM), renal cell carcinoma (RCC), urothelial cancers (US) relapse-remitting multiple sclerosis (RRMS), and Type 1 diabetes (T1D)

Key Topics Covered:

Chapter 1 Introduction

  • Introduction
  • Interleukin-2 an Important Driver for T Cell Homeostasis

Chapter 2 A Balancing Act

  • Targeted Effects
  • Off-Target Effects

Chapter 3 Approved IL-2 Therapies

  • IL-2 Antagonist Immunosuppressant
  • Simulet (Basilximab) Novartis
  • Zenapax (Daclizumab) Roche
  • Zinbryta (Daclizumab) AbbVie/Biogen
  • Leukotac (Iolimomab) ElsaLys Biotech
  • IL-2 Agonist Cancer Immunotherapy
  • Proleukin (Aldesleukin) Novartis/Chiron

Chapter 4 Future Opportunities

  • New Strategies to Harness IL-2's Potential
  • IL-2 Monoclonal Antibodies
  • IL-2 Antibody Drug Conjugates
  • IL-2 Antibody Cytokine Fusion Proteins
  • IL-2 Mutant Superkines
  • IL-2 Therapeutic Protein Inhibitor
  • IL-2 Immunotoxins
  • IL-2 Radioimmunoconjugates
  • Long-Acting Recombinant IL-2
  • IL-2 Based Vaccines

Chapter 5 IL-2 Watch for These Drugs

Chapter 6 References

List of Tables

Table 1: Expression of CD25, CD122 and CD132 in Immune and Nonimmune Cells

Table 2: Selection of Clinical Studies With IL-2 Drugs at Different Doses on Different Targets

Table 3: IL-2 Agents to Watch

List of Figures

Figure 1: IL-2 Signaling Pathways and Their Primary Biological Effects in Different Immune Cell Types

Figure 2: Three Different Types of IL-2 Receptors

Figure 3: Balancing Efficacy and Safety

Figure 4: Drugs Targeting IL-2

Figure 5: Computer Model of Neoleukin-2/15 Structure

Companies Mentioned

  • AbbVie
  • ADC Therapeutics
  • Anaveon AG
  • Biogen
  • Chiron
  • ElsaLys Biotech
  • Medicenna
  • Nektar Therapeutics
  • Novartis
  • Roche
  • Syncona
  • University of Zurich

For more information about this report visit https://www.researchandmarkets.com/r/ntz2g1

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Immune Disorders Drugs, Immunosuppressive Drugs